Brief: Bergenbio Announces Amendment To Accord Clinical Trial Protocol For Bemcentinib As Potential Treatment For Covid-19
08/07/2020 16:10
July 8 (Reuters) - Bergenbio ASA BGBIO.OL :
* BERGENBIO ANNOUNCES AMENDMENT TO THE ACCORD CLINICAL TRIAL
PROTOCOL FOR BEMCENTINIB AS POTENTIAL TREATMENT FOR COVID-19
* BERGENBIO-UNDER AMENDMENT PATIENTS TO POTENTIALLY RECEIVE
BEMCENTINIB PLUS ONE OR BOTH OF 2APPROVED COVID-19 TREATMENTS:
DEXAMETHASONE AND REMDESIVIR
Source text for Eikon: ID:nWkr5Zypf8
Further company coverage: BGBIO.OL
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncoinvent ASA
See all newsBrief: Oncoinvent To Raise Up To NOK 140 Million In Private Placement
Brief: Oncoinvent H1 Operating Loss NOK 69 Mln
Brief: Oncoinvent Secures New Patent Expanding Protection For Radspherin
Brief: Oncoinvent's Shares To Be Consolidated In Ratio Of 100:1
Brief: Oncoinvent To Increase Share Capital In Connection With Settlement Of Underwriting Fee